Last session

November 15, 2026

Argenx is buying Unnatural Products for up to $1.15 billion to build next-generation medicines.

What happened

Argenx said it will acquire Unnatural Products in a deal worth as much as $1.15 billion. Argenx shares fell 2.2 percent, a move larger than 76 percent of its daily changes over three years. The broader market slipped but its uptrend remained intact.

Why it matters

Argenx is spending a large sum to bring a new drug platform in-house. Paying up can make sense if the technology delivers new therapies, but the market treated it as an overpayment. The deal touches roughly 500 billion dollars of market value, so other biotech firms may get re-rated as investors weigh whether platform acquisitions are the new normal.

The case against

Argenx fell more than the market, suggesting investors worry about dilution or overpaying for early-stage science. The selloff could be a one day reaction, but a 2.2 percent drop on a calm day says the market saw real risk in the price tag.

What settles it

Whether Argenx stock recovers within a week will show if investors reconsider the deal's long-term payoff.

Companies in this story

All market stories

Decifer Markets is a media publication. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security.

DisclaimerTermsPrivacyAbout